What targeted therapy can and cannot do
Targeted cancer treatment acts on particular molecular features. That is the central distinction from chemotherapy, which affects dividing cells more broadly. Because the mechanism depends on a feature the tumour actually has, the same drug that helps one patient may offer no benefit to another whose tumour lacks the relevant marker.
This is why a targeted therapy question is really two questions: does the tumour have a feature the drug acts on, and is there a medicine that matches it? Biomarker findings can help clinicians assess potential treatment options. They do not by themselves prove that a particular drug will work, that it is the best next step, or that it is available where you plan to be treated.
What targeted therapy cannot do is equally important to state plainly. It cannot substitute for surgery, radiotherapy, chemotherapy or other treatment when those are the appropriate approach. It cannot create a target that is not present. It cannot promise a response, a cure or a fixed duration of benefit. And it cannot be selected responsibly from a pathology report alone without the treating clinician reviewing the whole case.
For an overseas patient, the practical consequence is that you are not asking a centre to sell you a drug. You are asking whether a qualified team, after reviewing your records, considers a targeted approach relevant to your situation and whether it can support that treatment and its monitoring.
Why biomarkers and previous drugs decide the conversation
Two record sets shape whether a targeted therapy discussion is useful: the molecular or biomarker results from your tumour, and the treatments you have already received. The first tells the clinician what features might be acted on. The second tells them what has already been tried, what happened, and what has changed since.
A biomarker result is not a prescription. A finding may be relevant to one class of treatment and not another, may need confirmation on a particular sample or test method, and may be interpreted differently depending on the cancer type and stage. Some findings are well established for specific cancers; others are still being studied. A clinician has to place your result in that context rather than read it as a standalone instruction.
Previous drugs matter because they change the question. If a targeted medicine has already been used and the cancer progressed, the team needs to understand when, at what dose, and with what response and side effects. If no targeted treatment has been used, the team needs to know which conventional treatments you have had and whether further standard options remain. This history also affects whether a new approach is being considered as a next line of treatment or as something else.
This is also where gaps in records become a real problem. If the biomarker report is missing, or the prior treatment history is only partly documented, the clinician cannot responsibly say whether a targeted approach is relevant. That does not mean you must delay necessary local care while assembling a file. It means the overseas enquiry should be clear about what is known, what is missing, and what still needs to be confirmed.
What a China centre has to confirm before you travel
A centre considering your case has to answer several questions that no article can answer for it. Can it assess your specific cancer type and biomarker context? Does it have the relevant expertise and the ability to review your pathology and molecular results? Can it continue the treatment and monitoring you need, rather than only offering an initial opinion?
Access is a separate question from clinical suitability. A medicine being used in one country does not establish that the same product, formulation or access route is available in China. Availability can depend on the hospital, the specific drug, the indication, and the regulatory and supply situation at the time. These are questions to put to the named provider, not assumptions to carry from one health system to another.
Continuity matters as much as the first appointment. If you are already on a targeted treatment, you need to know how the centre would manage ongoing dosing, monitoring, and management of side effects, and what would happen if the medicine were interrupted. If you are not yet on treatment, you need to know what the centre would need before it could advise, and what it could and could not offer.
It is reasonable to ask for written confirmation of what the centre can and cannot do for your case. A general statement that a hospital offers cancer care is not the same as confirmation that it can assess your biomarker context and support your treatment and monitoring.
The records that make an assessment possible
A useful records set for a targeted therapy enquiry is not the same as a complete medical archive. It is the specific material a clinician needs to judge whether a targeted approach is relevant and whether the centre can help. The exact list depends on your cancer type and history, so treat the following as items to discuss with the receiving team rather than a universal checklist.
Pathology and molecular reports are central. These include the original biopsy or surgical pathology report, any biomarker or genomic testing results, and information about the sample and test method where available. If testing was done at more than one point, the dates and sequence matter.
Treatment history should be documented clearly: which drugs were used, when, at what dose, for how long, and with what response and side effects. Imaging reports that show the disease over time help the clinician understand the trajectory. A short summary in your own words is useful, but it does not replace the underlying reports.
Current status and practical constraints also belong in the enquiry. That includes your current symptoms, any recent changes, the medicines you are taking, and what you are hoping to achieve. If you are seeking a second opinion rather than travel, say so. If you are considering travel, say that too, because it changes what the centre needs to confirm.
How to frame the questions you send
The quality of the reply often depends on the quality of the question. A message that asks whether a hospital offers targeted therapy will get a general answer. A message that states your cancer type, the biomarker results you have, the treatments you have already received, and the specific decision you are trying to make is far more likely to produce a useful response.
Ask directly whether the centre can assess your case given the records you have. Ask what it would need if something is missing. Ask whether it can continue an existing treatment and its monitoring, or whether it can only offer an initial opinion. Ask who would be responsible for decisions about starting, changing or stopping treatment, and how that would be communicated to you.
It also helps to ask what the centre cannot do. A clear statement of limits is more useful than a broad promise. If the centre cannot assess your biomarker context, cannot access a particular medicine, or cannot provide the monitoring your treatment requires, you need to know that before making travel plans.
Keep the first message short. A brief summary of the diagnosis, the key biomarker results, the treatments already received, and your main question is enough to begin. More detailed records can follow once the centre confirms it can review your case.
What this means for your next step
Targeted cancer therapy can address some cancers whose molecular features match an available approach. It cannot replace other treatment when those are appropriate, work without a relevant target, or guarantee a response. For care in China, the decision that matters is whether a qualified centre can assess your specific case and support your treatment and monitoring.
The practical next step is to gather the records that describe your tumour and your treatment history, then ask a centre directly whether it can review them and what it would need to advise you. An initial enquiry is free and does not commit you to travel or to buying a proxy consultation. The hospital decides whether it can accept your case, and no outcome is guaranteed.
If your symptoms are worsening or you need urgent care, that takes priority over an overseas enquiry and should be addressed locally first.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.